WP
ALXN

WMS Partners’s Alexion Pharmaceuticals ALXN Stock Holding History

WMS Partners’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-2,275
Closed -$272K – 243
2017
Q4 		$272K Buy
2,275
+170
+8% +$20.7K 0.03% 195
2017
Q3 		$295K Hold
2,105
– – 0.04% 174
2017
Q2 		$256K Sell
2,105
-5
-0.2% -$582 0.03% 183
2017
Q1 		$256K Hold
2,110
– – 0.03% 174
2016
Q4 		$258K Buy
2,110
+5
+0.2% +$612 0.03% 163
2016
Q3 		$258K Hold
2,105
– – 0.03% 165
2016
Q2 		$246K Sell
2,105
-1,500
-42% -$213K 0.03% 180
2016
Q1 		$502K Buy
3,605
+163
+5% +$23.9K 0.07% 115
2015
Q4 		$657K Buy
3,442
+87
+3% +$15.2K 0.09% 103
2015
Q3 		$525K Buy
3,355
+671
+25% +$122K 0.08% 108
2015
Q2 		$485K Buy
2,684
+544
+25% +$93.9K 0.06% 174
2015
Q1 		$371K Buy
2,140
+35
+2% +$6.33K 0.05% 193
2014
Q4 		$389K Hold
2,105
– – 0.06% 136
2014
Q3 		$349K Sell
2,105
-405
-16% -$66.5K 0.05% 170
2014
Q2 		$392K Sell
2,510
-550
-18% -$86.8K 0.06% 162
2014
Q1 		$466K Buy
3,060
+1,305
+74% +$208K 0.07% 148
2013
Q4 		$233K Buy
+1,755
New +$211K 0.04% 203

Other funds holding ALXN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

WMS Partners's ALXN Position: Q1 2018 in Review

WMS Partners sold out of Alexion Pharmaceuticals (ALXN) in Q1 2018, closing a stake of 2,275 shares — an estimated $272K sold.

WMS Partners first reported a position in ALXN in Q4 2013 and held it in 17 quarters. The position peaked at $657K in Q4 2015. 597 funds tracked by Wall St. Rank hold ALXN as of Q1 2018.

  • WMS Partners reported no remaining Alexion Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • WMS Partners sold 2,275 Alexion Pharmaceuticals shares in Q1 2018, an estimated $272K.
  • WMS Partners first reported a position in Alexion Pharmaceuticals in Q4 2013 and held it in 17 quarters.
  • WMS Partners's Alexion Pharmaceuticals position peaked at $657K in Q4 2015.
  • 597 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2018.

Based on WMS Partners's 13F filing for Q1 2018, filed 14 May 2018.